Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 21 - 30 of 430

Selected Filters:
12 December 2025

The Dual Prevention Pill Inspiration Guide

This Dual Prevention Pill (DPP) “inspiration guide,” developed by AVAC, is designed to equip implementers, health practitioners, public health advocates, and community leaders with the proven methods, insights, and creative strategies needed to effectively market and communicate the DPP to relevant audiences.

Demand Creation/Marketing

Document
10 December 2025

The Dual Prevention Pill: A catalyst for integrated HIV and family planning services in Zambia: A policy brief

This policy brief, developed by Copper Rose Zambia and AVAC, presents findings from assessments conducted at seven public health facilities, three community hubs, and five pharmacies which reveal readiness and willingness to deliver the Dual Prevention Pill across various service delivery platforms, especially in community settings.

Community/Advocacy, Normative Guidance/Policies

Document
8 December 2025

South Africa Lenacapavir Implementation Guidelines, 2025

This guideline, developed by South Africa’s National Department of Health, is intended to provide comprehensive clinical, programmatic, and operational direction for the safe, effective, and equitable rollout of lenacapavir as a long-acting injectable option for HIV PrEP in South Africa.

Normative Guidance/Policies

Document
26 November 2025

A Dual Prevention Pill for HIV & Pregnancy Prevention: A pilot study among adolescent girls and young women in Zimbabwe

This article from AIDS and Behavior describes the results of a study examining whether an over-encapsulated dual prevention pill (DPP) combining PrEP + oral contraceptive would be preferred, acceptable, and improve adherence compared to PrEP alone amongst adolescent girls and young women in Zimbabwe.

Research

External Link
21 November 2025

Women’s Preferences for Integrating Multi-product Pre-exposure Prophylaxis Delivery Programs within Services for Sexually Transmitted Infections and Reproductive Health Care in Uganda: A discrete choice experiment

This article from Frontiers in Reproductive Health describes the results of a cross-sectional discrete choice experiment to determine the most preferred attributes and levels of multi-product PrEP programs for adolescent girls and young women in Uganda.

Research, Service Delivery

External Link
3 November 2025

Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda, 2022

These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.

Normative Guidance/Policies

Document
16 October 2025

Preferences for Long-acting Injectable HIV Pre-exposure Prophylaxis Service Delivery among Male and Female Sex Workers in Uganda: A discrete choice experiment

This article from PLOS Global Public Health explores service delivery preferences for injectable cabotegravir among heterosexual male sex workers and female sex workers in Uganda.

Research, Service Delivery

External Link
9 October 2025

The Impact of Cuts in the US President’s Emergency Plan for AIDS Relief Funding for HIV Pre-exposure Prophylaxis in Sub-Saharan Africa: A modelling study

This article from The Lancet HIV estimates the impact of the PEPFAR funding pause for PrEP on HIV infections in sub-Saharan Africa.

Research

External Link
30 September 2025

Prevention with PURPOSE

This presentation, delivered by Dr Linda-Gail Bekker at IAS 2025, provides an overview of PURPOSE 1 and 2 lenacapavir clinical trial results as well as special considerations for administration to different populations and drug-drug interactions.

Research

Presentation
30 September 2025

Dynamic Choice HIV Prevention with Long-acting Injectable Cabotegravir Pre-exposure Prophylaxis in East, Central, Southern, and West Africa: A cost-effectiveness modelling analysis

In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention intervention that offered structured choice of biomedical prevention product and opportunity to change products over time substantially improved prevention coverage; incident HIV infections were eliminated when long-acting cabotegravir was included as an option. This article from The Lancet HIV aims to assess…

Financing & Costing, Research, Service Delivery

External Link